GLYSTALI
Live / Applied — Fourth extension granted (statement of use) (as of 15 Jul 2025)
What this means for you
Not registered yet, but its 10 Jun 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97453092
- Mark type
- Stylized text
- Filed
- 10 Jun 2022
- Published for opposition
- 30 May 2023
- Attorney of record
- Anthony J. DiMarino
Goods and services
- Class 005 — Pharmaceuticals: Anti-inflammatories; Antibacterial pharmaceuticals; Cardiovascular pharmaceuticals; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations for the treatment and prevention of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; Pharmaceutical preparations for the treatment and prevention of hematalogic disorders and for use in tissue and organ transplantation; Pharmaceutical preparations for the treatment and prevention of eye diseases and conditions; Pharmaceutical preparations for the treatment and prevention of heart rhythm disorders; Pharmaceutical preparations for the treatment and prevention of immune system related diseases and disorders; Pharmaceutical preparations for the treatment and prevention of kidney diseases; Pharmaceutical preparations for the treatment and prevention of hypertension; Pharmaceutical preparations for the treatment and prevention of skin disorders; Pharmaceutical preparations for the treatment and prevention of cancer and tumors; Pharmaceutical preparations for the treatment and prevention of allergies; Pharmaceutical preparations for the treatment and prevention of bone diseases; Pharmaceutical preparations for the treatment and prevention of respiratory diseases and asthma; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical products for ophthalmological use
Owner
- Zydus Pharmaceuticals (USA) Inc., Pennington, NJ, US
- Zydus Pharmaceuticals (USA) Inc., Pennington, NJ, US
Prosecution history
- 15 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 15 Jul 2025 — SOU EXTENSION 4 GRANTED
- 14 Jul 2025 — SOU EXTENSION 4 FILED
- 14 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jan 2025 — SOU EXTENSION 3 GRANTED
- 06 Jan 2025 — SOU EXTENSION 3 FILED
- 06 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2024 — SOU EXTENSION 2 GRANTED
- 24 Jun 2024 — SOU EXTENSION 2 FILED
- 24 Jun 2024 — SOU TEAS EXTENSION RECEIVED
- 21 Dec 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Dec 2023 — SOU EXTENSION 1 GRANTED